See every side of every news story
Published loading...Updated

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy - Financial News Media

Summary by Financial News Media
New York, NY - March 20, 2025 - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to ex
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Financial News Media broke the news in on Thursday, March 20, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.